Borchmann P - Search Results

1

Outcome of Patients With Early-Stage Infradiaphragmatic Hodgkin Lymphoma: A Comprehensive Analysis From the German Hodgkin Study Group.

Sasse S, Goergen H, Plütschow A, Böll B, Eichenauer DA, Fuchs M, Behringer K, Zijlstra JM, Greil R, Markova J, Topp MS, Meissner J, Neubauer A, Baues C, Engert A, Borchmann P, von Tresckow B. Sasse S, et al. Among authors: borchmann p. J Clin Oncol. 2018 Sep 1;36(25):2603-2611. doi: 10.1200/JCO.2018.78.7192. Epub 2018 Jul 10. J Clin Oncol. 2018. PMID: 29989855 Clinical Trial.

2

A phase I/II study of idarubicin, dexamethasone and interferon-alpha (I-Dexa) in patients with relapsed or refractory multiple myeloma.

Hübel K, Tesch H, Kröger B, Schnell R, Borchmann P, Diehl V, Engert A. Hübel K, et al. Among authors: borchmann p. Leukemia. 1997 Dec;11 Suppl 5:S47-51. Leukemia. 1997. PMID: 9436939 Clinical Trial.

3

DIZE (dexamethasone, idarubicin, and continuous infusion of ifosfamide and etoposide): an effective and well-tolerated new regimen for patients with relapsed lymphoma.

Reiser M, Schnell R, Straub G, Borchmann P, Wilhelm M, Ubelacker R, Wörmann B, Münch R, Diehl V, Engert A. Reiser M, et al. Among authors: borchmann p. Leuk Lymphoma. 1998 Oct;31(3-4):359-66. doi: 10.3109/10428199809059229. Leuk Lymphoma. 1998. PMID: 9869200 Clinical Trial.

4

New drugs in the treatment of Hodgkin's disease.

Borchmann P, Schnell R, Diehl V, Engert A. Borchmann P, et al. Ann Oncol. 1998;9 Suppl 5:S103-8. doi: 10.1093/annonc/9.suppl_5.s103. Ann Oncol. 1998. PMID: 9926247 Review.

5

Treatment of refractory Hodgkin's lymphoma patients with an anti-CD25 ricin A-chain immunotoxin.

Schnell R, Vitetta E, Schindler J, Borchmann P, Barth S, Ghetie V, Hell K, Drillich S, Diehl V, Engert A. Schnell R, et al. Among authors: borchmann p. Leukemia. 2000 Jan;14(1):129-35. doi: 10.1038/sj.leu.2401626. Leukemia. 2000. PMID: 10637488 Clinical Trial.

6

Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma.

Borchmann P, Schnell R, Knippertz R, Staak JO, Camboni GM, Bernareggi A, Hübel K, Staib P, Schulz A, Diehl V, Engert A. Borchmann P, et al. Ann Oncol. 2001 May;12(5):661-7. doi: 10.1023/a:1011139016294. Ann Oncol. 2001. PMID: 11432625 Free article. Clinical Trial.

7

A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma.

Schnell R, Staak O, Borchmann P, Schwartz C, Matthey B, Hansen H, Schindler J, Ghetie V, Vitetta ES, Diehl V, Engert A. Schnell R, et al. Among authors: borchmann p. Clin Cancer Res. 2002 Jun;8(6):1779-86. Clin Cancer Res. 2002. PMID: 12060617 Clinical Trial.

8

Current strategies of antibody-based treatment in Hodgkin's disease.

Schnell R, Borchmann P, Schulz H, Engert A. Schnell R, et al. Among authors: borchmann p. Ann Oncol. 2002;13 Suppl 1:57-66. doi: 10.1093/annonc/13.s1.57. Ann Oncol. 2002. PMID: 12078905 Free article. Review.

9

Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma.

Borchmann P, Schnell R, Fuss I, Manzke O, Davis T, Lewis LD, Behnke D, Wickenhauser C, Schiller P, Diehl V, Engert A. Borchmann P, et al. Blood. 2002 Nov 1;100(9):3101-7. doi: 10.1182/blood-2001-12-0295. Blood. 2002. PMID: 12384405 Free article. Clinical Trial.

10

Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin's lymphoma.

Schnell R, Borchmann P, Staak JO, Schindler J, Ghetie V, Vitetta ES, Engert A. Schnell R, et al. Among authors: borchmann p. Ann Oncol. 2003 May;14(5):729-36. doi: 10.1093/annonc/mdg209. Ann Oncol. 2003. PMID: 12702527 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

247 results

Search Page